Abstract
Respiratory syncytial virus has been an ongoing health problem for 50 years. Hospitalization rates due to virus-induced respiratory illness continue to be substantial for infants, small children, the elderly and the immunocompromised. The only currently available treatments are a broad-spectrum antiviral and two immunoprophylactic antibodies, all of which are reserved for high-risk patients. The combination of this limited therapeutic repertoire and the lack of a vaccine clearly demonstrates the need to continue the search for more efficacious and safe agents against respiratory syncytial virus. The following is a review on the current progress of that search.
Original language | English (US) |
---|---|
Pages (from-to) | 625-639 |
Number of pages | 15 |
Journal | Expert Review of Anti-Infective Therapy |
Volume | 2 |
Issue number | 4 |
DOIs | |
State | Published - Aug 2004 |
Externally published | Yes |
Keywords
- Antivirals
- Entry/fusion
- IMPDH
- Inhibitor
- RSV
- Respiratory syncytial virus
- Ribavirin
- Small molecule
ASJC Scopus subject areas
- Microbiology
- Microbiology (medical)
- Virology
- Infectious Diseases